Heart failure arises when the heart’s ability to pump blood around the body is impaired. This deprives the body’s tissues of the oxygen and nutrients upon which their survival depends. It commonly occurs as a result of conditions such as ischaemic heart disease, diabetes and high blood pressure.
Heart failure may be classified as being either acute or chronic. Acute heart failure is characterised by a sudden onset of symptoms, whereas in chronic heart failure typically develops and worsens over time.
Examples of the symptoms associated with heart failure include dyspnoea, fatigue, difficulty exercising, and oedema, particularly peripheral oedema. Symptoms may vary depending on which side or sides of the heart are affected.
Featured Learning Zones
Welcome to the Fluid Management Learning Zone. In this Learning Zone we provide an overview of fluid management, including albumin for sepsis and septic shock, guidelines for fluid management in liver cirrhosis and fluid management in cardiac surgery.
Related news and insights
Neovasc Inc. announced that the FDA’s Circulatory System Devices Advisory Panel voted 14 to 4 “in favor” that the Neovasc Reducer is safe when used as intended, and voted 1 to 17 “against” on the issue of a reasonable assurance of effectiveness.
Findings from a new exploratory sub-analysis of the EMPEROR-Reduced phase III trial showed that Jardiance (empagliflozin) reduced the risk of adverse cardiovascular and kidney events in adults with heart failure with reduced ejection fraction – with and without diabetes – regardless of chronic kidney disease status at baseline.
AstraZeneca’s Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes (T2D).
An update of the 2012 systematic review and meta-analyses were performed and a modified-GRADE approach was used to update the recommendation for the use of adaptive servo-ventilation (ASV) for the treatment of central sleep apnea syndrome (CSAS)...
You may be interested in...
The Union-North America Region (NAR) is the regional arm of the International Union against Tuberculosis and Lung Disease (The Union), a global public health organization with the vision to provide health solutions to the poor.
28th Conference On Retrovirus And Opportunistic Infections 2021
CROI is the preeminent meeting in the world and attracts more than 4,000 research leaders from nearly 90 countries and nearly half of CROI attendees come from outside the United States. In recent years, more than 1000 abstracts have been selected for presentation at CROI.